Last reviewed · How we verify
ME1100 inhalation solution
At a glance
| Generic name | ME1100 inhalation solution |
|---|---|
| Also known as | Arbekacin inhalation solution, arbekacin, ME1100 |
| Sponsor | Meiji Seika Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia (PHASE1)
- Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers (PHASE1)
- Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ME1100 inhalation solution CI brief — competitive landscape report
- ME1100 inhalation solution updates RSS · CI watch RSS
- Meiji Seika Pharma Co., Ltd. portfolio CI